Dysregulation of the type I interferon system in adult-onset clinically amyopathic dermatomyositis has a potential contribution to the development of interstitial lung disease
- PMID: 23013528
- DOI: 10.1111/j.1365-2133.2012.11145.x
Dysregulation of the type I interferon system in adult-onset clinically amyopathic dermatomyositis has a potential contribution to the development of interstitial lung disease
Abstract
Background: It has been speculated that viral infection might be one of the potential aetiologies for adult-onset clinically amyopathic dermatomyositis (CADM). The molecular pathogenesis remains largely unknown.
Objectives: To explore whether dysregulation of the type I interferon (IFN) system is involved in the pathogenesis of CADM.
Methods: We studied 16 patients with CADM and compared them with healthy control subjects (n = 20) and patients with classic dermatomyositis (DM, n = 16) and polymyositis (PM, n = 16). Expressions of mRNA for serial toll-like receptor genes (TLR2, TLR3, TLR4, TLR7, TLR8 and TLR9) and type I IFN-regulated genes (IRF7, ISG15 and MxA) in peripheral blood leucocytes (PBL) were detected by real-time polymerase chain reaction analysis. The level of IFN-α in blood was tested by enzyme-linked immunosorbent assay.
Results: The mRNA expressions of TLR7, TLR9 and IRF7 were greatly elevated in the PBL from patients with CADM compared with controls. Upregulation of the ISG15 and MxA genes was detected in the PBL from patients with CADM, as well as from patients with classic DM. Among the four study groups, the overproduction of IFN-α in blood was most significant in the CADM group. Especially, IFN-α level was obviously high in the clinical interstitial lung disease (ILD) subgroup of patients with CADM. Positive correlations were found between IFN-α concentration and other unfavourable prognostic factors of CADM-associated ILD.
Conclusions: Our data suggest that the dysregulation of the type I IFN system may be implicated in CADM pathogenesis. IFN-α may be a useful biomarker for assessing the disease severity of CADM-associated ILD.
© 2012 The Authors. BJD © 2012 British Association of Dermatologists 2012.
Similar articles
-
Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis.Arthritis Care Res (Hoboken). 2016 May;68(5):689-94. doi: 10.1002/acr.22728. Arthritis Care Res (Hoboken). 2016. PMID: 26414240 Free PMC article.
-
Serum IL8 and mRNA level of CD11b in circulating neutrophils are increased in clinically amyopathic dermatomyositis with active interstitial lung disease.Clin Rheumatol. 2016 Jan;35(1):117-25. doi: 10.1007/s10067-015-3080-1. Epub 2015 Oct 12. Clin Rheumatol. 2016. PMID: 26459323
-
Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease.Mod Rheumatol. 2013 May;23(3):496-502. doi: 10.1007/s10165-012-0663-4. Epub 2012 May 29. Mod Rheumatol. 2013. PMID: 22644102
-
Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis.Arthritis Care Res (Hoboken). 2013 Aug;65(8):1316-24. doi: 10.1002/acr.21985. Arthritis Care Res (Hoboken). 2013. PMID: 23908005 Review.
-
A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies.J Am Acad Dermatol. 2006 Apr;54(4):597-613. doi: 10.1016/j.jaad.2005.10.041. Epub 2006 Jan 23. J Am Acad Dermatol. 2006. PMID: 16546580 Review.
Cited by
-
Effect of high-dose intravenous methylprednisolone pulse (IVMP) therapy in the survival of patients with anti-melanoma differentiation-associated gene 5-related rapidly progressive interstitial lung disease: a retrospective analysis.Clin Rheumatol. 2024 Mar;43(3):1135-1143. doi: 10.1007/s10067-024-06872-0. Epub 2024 Jan 30. Clin Rheumatol. 2024. PMID: 38289569
-
Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider.RMD Open. 2023 Mar;9(1):e002864. doi: 10.1136/rmdopen-2022-002864. RMD Open. 2023. PMID: 36882218 Free PMC article.
-
Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider.RMD Open. 2023 Mar;9(1):e002876. doi: 10.1136/rmdopen-2022-002876. RMD Open. 2023. PMID: 36863752 Free PMC article.
-
Clinical Characteristics and Management of Patients With Clinical Amyopathic Dermatomyositis: A Retrospective Study of 64 Patients at a Tertiary Dermatology Department.Front Med (Lausanne). 2021 Dec 2;8:783416. doi: 10.3389/fmed.2021.783416. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34926528 Free PMC article.
-
Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry.Rheumatol Int. 2021 Jun;41(6):1021-1036. doi: 10.1007/s00296-021-04819-1. Epub 2021 Mar 27. Rheumatol Int. 2021. PMID: 33774723 Free PMC article. Review.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
